相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF(V600E) metastatic colorectal cancer
Van K. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma
Shao-Lai Zhou et al.
JAMA SURGERY (2022)
Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases
Dario Baratti et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
Francois Quenet et al.
LANCET ONCOLOGY (2021)
Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type
Amin H. Nassar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)
Vincent C. J. van de Vlasakker et al.
EJSO (2021)
Definition and Prediction of Early Recurrence and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: Towards Predicting Oncologic Futility Preoperatively
Caroline J. Rieser et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
Wilhelm Graf et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis
V. Narasimhan et al.
COLORECTAL DISEASE (2020)
The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Jolene Si Min Wong et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2020)
Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review and discussion of latest controversies
Michael Flood et al.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study
Judith E. K. R. Hentzen et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience
Vignesh Narasimhan et al.
DISEASES OF THE COLON & RECTUM (2019)
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A. Fabrizio et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
High concordance rate of KRAS/BRAF mutations. and MSI-H between primary colorectal cancer and corresponding metastases
Kenji Fujiyoshi et al.
ONCOLOGY REPORTS (2017)
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jeremy C. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers A Secondary Analysis of 2 Randomized Clinical Trials
Frank A. Sinicrope et al.
JAMA ONCOLOGY (2017)
Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastasis in Norway: Prognostic Factors and Oncologic Outcome in a National Patient Cohort
Ida S. Froysnes et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
What Made Hyperthermic Intraperitoneal Chemotherapy an Effective Curative Treatment for Peritoneal Surface Malignancy: A 25-Year Experience With 1,125 Procedures
Guillaume Passot et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
S. Renaud et al.
BRITISH JOURNAL OF CANCER (2015)
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial
D. Klingbiel et al.
ANNALS OF ONCOLOGY (2015)
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch et al.
CLINICAL CANCER RESEARCH (2014)
Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Affect Long-term Outcome of Patients With Peritoneal Metastases From Colorectal Cancer: a Two-Center Study of 101 Patients
D. Baratti et al.
DISEASES OF THE COLON & RECTUM (2014)
Combined Microsatellite Instability and BRAF Gene Status As Biomarkers for Adjuvant Chemotherapy in Stage III Colorectal Cancer
Akira Ooki et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases
Jean-Nicolas Vauthey et al.
ANNALS OF SURGERY (2013)
Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
Christopher G. Smith et al.
CLINICAL CANCER RESEARCH (2013)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M. Koopman et al.
BRITISH JOURNAL OF CANCER (2009)
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer
VJ Verwaal et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
